- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Palbociclib/Fulvestrant Combo Maintains OS Benefit in HR+ Breast Cancer
June 5th 2021, 8:20pm
At a median follow-up of 73.3 months, investigators in the PALOMA-3 trial have concluded that palbociclib plus fulvestrant maintains a clinically meaningful improvement in overall survival compared with placebo plus fulvestrant for patients with HR-positive, HER2-negative advanced breast cancer.
Dr. Slamon on the Benefit of Ribociclib Plus Fulvestrant in HR+/HER2- Advanced Breast Cancer
June 5th 2021, 8:06pm
Dennis J. Slamon, MD, PhD, discusses the long-term benefit of ribociclib plus fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer.
Alectinib Fails to Improve OS in ALK-Positive NSCLC
June 5th 2021, 7:17pm
In a final overall survival analysis of the J-ALEX study, patients with non-small cell lung cancer receiving alectinib failed to achieve better results than patients receiving crizotinib.
Tucatinib Plus Trastuzumab/Capecitabine Maintain Survival Benefit in HER2-Positive Breast Cancer
June 5th 2021, 6:41pm
Tucatinib plus trastuzumab and capecitabine maintained and even improved overall survival over placebo in pretreated patients with HER2-positive breast cancer.
Selpercatinib Effective in RET Fusion–Positive NSCLC, Irrespective of Prior Therapies
June 5th 2021, 6:11pm
Treatment with selpercatinib demonstrated consistent efficacy in patients with RET fusion-positive non-small cell lung cancer, regardless of prior treatments.
Single Agent and Combination TG-1701 Yield Promising Clinical Activity in CLL and Other B-Cell Malignancies
June 5th 2021, 6:08pm
TG-1701 demonstrated encouraging clinical and pharmacodynamic activity at all dose levels in patients with B-cell malignancies.
Larotrectinib Elicits Robust Responses in TRK Fusion Cancer
June 5th 2021, 5:31pm
The highly selective, central nervous system-active TRK inhibitor larotrectinib yielded promising response rates in patients with TRK fusion cancer, including in those with CNS metastases at baseline.
Pralsetinib Elicits Durable Anti-Tumor Effects in RET Fusion+ Solid Tumors
June 5th 2021, 4:53pm
Pralsetinib demonstrated robust and durable anti-tumor activity, as well as a tolerable safety profile, in heavily pretreated patients with multiple RET fusion–positive advanced solid tumors.
Niraparib Individualized Starting Dose Tolerable in Platinum-Sensitive Recurrent Ovarian Cancer
June 5th 2021, 4:41pm
Niraparib, when delivered at an individualized starting dose, was found to be well tolerated in patients with platinum-sensitive recurrent ovarian cancer.
Mosunetuzumab-Polatuzumab Vedotin Combo Effective, Well Tolerated in R/R B-NHL
June 5th 2021, 4:35pm
Two cases of cytokine release syndrome occurred during the first cycle of step-up dosing; however, both were considered non-severe and were treated without the need of tocilizumab, admission to the ICU or use of vasopressors.
First-Line Ibrutinib Yields 7-Year Survival Benefit in CLL
June 5th 2021, 4:03pm
Single-agent ibrutinib given in the first-line setting sustained a progression-free survival and overall survival benefit compared with chlorambucil as therapy for patients with chronic lymphocytic leukemia at 7-year follow-up.
Zenocutuzumab Demonstrates Clinical Activity in a Variety of NRG1+ Cancers
June 5th 2021, 2:59pm
Zenocutuzumab represents a promising novel targeted therapeutic option for patients with NRG1 fusion–positive cancers.
Aumolertinib Prolongs Survival, Duration of Response in NSCLC
June 5th 2021, 2:30pm
Treatment with aumolertinib was associated with prolonged survival and duration of response in patients with non–small cell lung cancer.
Triplet Combination Safe, Effective for Relapsed/Refractory DLBCL
June 5th 2021, 2:15pm
Patients with relapsed/refractory diffuse large B-cell lymphoma treated with a novel combination of polatuzumab vetodin, rituximab and lenalidomide contributed to an improved overall response and complete response, with 82% remaining in remission at the study’s cutoff date.
Dr. Bonvalot on the Long-Term Safety of NBTXR3 Plus Radiotherapy in Locally Advanced Soft Tissue Sarcoma
June 5th 2021, 1:36am
Sylvie Bonvalot, MD, PhD, HDR, discusses the long-term safety of NBTXR3 plus radiotherapy in patients with locally advanced soft tissue sarcoma who were treated in the phase 2/3 Act.In.Sarc trial.
Allogeneic HCT Plus Reduced Intensity Conditioning With Bortezomib Triplet Is Safe in Multiple Myeloma
June 5th 2021, 1:30am
Allogeneic hematopoietic cell transplantation was safe when used with a reduced-intensity conditioning regimen of bortezomib, fludarabine, and melphalan in patients with high-risk multiple myeloma.
Sotorasib Impresses With Durable Clinical Benefit in KRAS p.G12C+ NSCLC
June 5th 2021, 12:51am
Sotorasib provided continued durable clinical benefit in patients with pretreated KRAS p.G12C–mutated non–small cell lung cancer.
Brexucabtagene Autoleucel Induces High, Durable Responses in Heavily Pretreated Relapsed/Refractory B-ALL
June 5th 2021, 12:29am
A single infusion of brexucabtagene autoleucel, a CAR T-cell therapy, demonstrated robust and durable responses in heavily pretreated patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Amivantamab/Lazertinib Yields Durable Responses in Osimertinib-Relapsed, Chemo-Naïve EGFR+ NSCLC
June 5th 2021, 12:09am
Amivantamab in combination with lazertinib elicited responses in more than one-third of chemotherapy-naïve patients with EGFR-mutant non–small cell lung cancer who had progressed on osimertinib.
Lifileucel/Pembrolizumab Elicits Encouraging ORR in ICI-Naïve Advanced Melanoma
June 4th 2021, 11:39pm
The addition of lifileucel to pembrolizumab resulted in an overall response rate of 85.7% compared with pembrolizumab alone in patients with immune checkpoint inhibitor–naïve advanced melanoma.